Does self-monitoring and self-management of blood pressure after stroke or transient ischemic attack improve control? TEST-BP, a randomized controlled trial Hypertension is the most important modifiable risk factor for primary and secondary stroke prevention, even modest reductions in clinic blood pressure (BP) of approximately 10/5 mm Hg being associated with a 30% risk reduction.
rates of BP control after stroke are poor, a recent cohort reporting only 16% of patients achieving clinic BP ≤130/80 mm Hg 6 months after their event. 2 Studies suggest that self-BP monitoring (SBPM) may improve BP control, its use resulting in lower BP levels and increased achievement of targets compared with usual management, particularly if combined with complementary strategies, such as telemonitoring of results, or guided antihypertensive self-management. 3 However, studies to date have not addressed the use of SBPM in high-risk groups.
Here we report the results of the TEST-BP trial, which aimed to determine whether SBPM with or without guided self-management of BP treatment resulted in lower BP levels and better control than usual care in hypertensive patients with a recent stroke or transient ischemic attack (TIA).
Methods
TEST-BP was a randomized, blinded end-point, parallel-group controlled trial (ClinicalTrials.gov reference no. NCT02947490). Summary methods are described, with full methodology available (online supplement). Eligible patients were adults with a recent mild/moderate stroke or TIA, all requiring BP treatment for secondary prevention. Patients with life expectancy less than 6 months or cognitive impairment were excluded. Ethical approval for the trial was granted (Research Ethics Committee East of England -Norfolk [Reference No. 11/EE/0147]). All participants provided written informed consent. At enrollment, participants were randomized via a concealed Web-based system to Treatment As Usual (TAU), Self-MONitoring only (S-MON), or Selfmonitoring with guided self-MANagement of BP (S-MAN).
Ambulatory BP monitoring (ABPM; Spacelabs 90207 monitor; Spacelabs Healthcare Ltd, Hertford, UK), undertaken as per guidelines, 4 was performed at baseline and 6 months in the 3 groups. Blood pressure management for TAU participants was by their general practitioner (GP) only. The intervention groups performed self-monitoring, as per guidelines, 4 at 6 weeks and at 3 and 5 months after randomization. S-MON patients used a validated monitor (Omron 705IT; Omron Healthcare UK Ltd, Milton Keynes, UK) with readings passed to the GP for management. S-MAN patients used a validated monitor (A&D UA-767PBT; A&D Instruments Ltd, Abingdon, UK) with telemonitoring (iModem; Netmedical, Utrecht, the Netherlands), readings going directly to the trial team. Changes to antihypertensive treatment in S-MAN group were made jointly by the patient and the supervising stroke trial clinician, but informing the patient's GP. British guidelines current at trial inception recommended a secondary stroke prevention target clinic BP of ≤130/80 mm Hg, with out-of-office BP targets adjusted down by 10/5 mm Hg because of expected differences in measurement methods, 5 so out-of-office target BP was ≤120/75 mm Hg.
The primary outcome was difference in daytime ambulatory systolic BP (SBP) at 6 months. Secondary outcomes were (i) differences in mean daytime ambulatory diastolic BP (DBP) at 6 months, (ii) differences in antihypertensive medication changes, and (iii) adverse events.
Participants with b14 daytime ABPM readings or noncompliant with self-monitoring were excluded from analysis. To detect a difference in mean daytime ambulatory SBP of 6 mm Hg, with a power of 0.8 at the 5% significance level, assuming an SD of 10.3 mm Hg for daytime ABPM, 6 required 48 participants per group.
Outcomes analysis
Data were analyzed using SPSS version 23.0 on an intention to treat basis (SPSS, Chicago, IL). Continuous data are presented as mean (SD) or mean (95% confidence interval [CI]), discrete data as median (interquartile range). Independent-samples t tests assessed between-group differences in mean BP at outcome and χ 2 tests assessed proportions of participants who were normotensive at outcome and proportions of participants who had medication changes. Mann-Whitney U tests assessed between-group differences in medication changes. Each intervention group was compared separately to control, with exploratory comparison of the intervention groups only where both were significantly different to control, to reduce the risk of a false positive outcome and to eliminate potential bias from using distinct control groups. 7 Sensitivity analysis accounting for missing ABPM data was conducted after imputation by predictive mean matching.
Results
Recruitment ran from December 20, 2012, to March 14, 2016, ending when target numbers were achieved. Progress through the trial is shown in Figure, with baseline demographics in Table I .
There were no significant between-group differences in the primary outcome of mean daytime ambulatory SBP at 6 months (difference TAU minus S-MON, 2.69 mm Hg [95% CI, −2.59 to 7.97; P = .31]; TAU minus S-MAN, 3.00 mm Hg [95% CI, −2.53 to 8.54; P = .28]) or in mean daytime ambulatory DBP (Table II) 
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American Heart Journal P = .001), although there was no difference with S-MON (31% vs 43% P = .19). The difference with S-MAN was driven by a greater number of dose increases (TAU vs S-MAN, P ≤ .0001). The number of dose decreases, additional, or discontinued medications did not differ.
Ninety-two percent of SBPM recording sets were completed. Only 1 participant was noncompliant with self-monitoring. In comparison, most TAU participants consulted their GP once during the trial (median, 1.0, interquartile range, 0.0-2.0). Rates of reported adverse effects were similar in all groups, and no major adverse events were recorded.
Discussion
Our findings, in agreement with comparable studies, showed that SBPM alone, or combined with telemonitoring and guided therapy management, did not result in lower BP levels or improved BP control at 6 months compared with usual care, despite good adherence. In a trial of SBPM alone versus usual care in hypertensive stroke patients, clinic BP at 6 or 12 months was not significantly different with intervention. 8 Post hoc analysis suggested a benefit in participants with baseline clinic BP of N140/90 mm Hg, but we did not find this.
Similarly, when investigating SBPM with guided self-management versus usual care in a mixed high-risk population, intervention did not result in lower clinic BP at 12 months in the subgroup with stroke/TIA. 9 Conversely, a feasibility study of SBPM telemonitoring versus usual care after stroke reported ambulatory SBP reductions of 10.1 mm Hg at 6 months with intervention compared with 3.8 mm Hg with control. 6 The only meta-analysis to assess patients with cerebrovascular disease as a subgroup found no benefit with intervention, although this finding may reflect small numbers and few trials using SBPM with additional strategies. Self-BP monitoring cannot intrinsically lower BP; rather, its effect is mediated through therapeutic intensification, [8] [9] [10] as we found, which is less likely to occur in patients with controlled BP. Alternatively, patients with physical (or cognitive) disability after stroke may gain less benefit from SBPM due to therapeutic inertia, as noted by Kerry et al. 8 These findings suggest that not all patients after stroke will benefit from SBPM. Strengths of this study include the use of the criterion-standard ABPM for the BP outcome measure, 4 differentiating it from most similar studies and reducing measurement and observer bias, and the simultaneous comparison of 2 interventions of differing intensity. The main limitation is the smaller between-group BP difference than planned in our sample size calculation; hence, our study may be underpowered to make firm conclusions about the significance of a more modest, but potentially clinically important SBPM effect. Second, our self-monitoring target may have been too low (just 10 participants reached target BP on the final self-monitoring), with recent comparisons suggesting that out-of-office values are on average 4/3 mm Hg lower than clinic measurements. 11 Third, although most participants had baseline daytime ABPM above our defined target, mean BP levels were approximately 135/75 mm Hg and all participants were on treatment, potentially limiting the benefit of the interventions. Finally, the use of different home monitors may have introduced measurement bias, although we would stress that both are validated. In summary, SBPM with or without guided self-management of antihypertensive therapy was safe and well tolerated, but did not improve overall BP control in these poststroke participants. The small reductions in BP demonstrated with SBPM in this trial may still be clinically significant and warrant further investigation to identify potential subgroups where such therapy may be clinically beneficial. 
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